

Resource Summary Report

Generated by [RRID](#) on Aug 13, 2026

beta-Tubulin (9F3) Rabbit mAb (HRP Conjugate)

RRID:AB_1950376

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5346, RRID:AB_1950376

Antibody Information

URL: http://antibodyregistry.org/AB_1950376

Proper Citation: Cell Signaling Technology Cat# 5346, RRID:AB_1950376

Target Antigen: beta-Tubulin (9F3) Rabbit mAb (HRP Conjugate)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W. Consolidation on 11/2018: AB_10694412, AB_1950376.

Antibody Name: beta-Tubulin (9F3) Rabbit mAb (HRP Conjugate)

Description: This monoclonal targets beta-Tubulin (9F3) Rabbit mAb (HRP Conjugate)

Target Organism: b, rat, h, m, mouse, r, bovine, z, human, mk

Antibody ID: AB_1950376

Vendor: Cell Signaling Technology

Catalog Number: 5346

Record Creation Time: 20250820T003559+0000

Record Last Update: 20250820T084154+0000

Ratings and Alerts

No rating or validation information has been found for beta-Tubulin (9F3) Rabbit mAb (HRP Conjugate).

No alerts have been found for beta-Tubulin (9F3) Rabbit mAb (HRP Conjugate).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Postlmayr A, et al. (2026) Functionally distinct ALK and ROS1 fusions detected in infant-type hemispheric gliomas converge on STAT3 and SHP2 activation. *Cell reports*, 45(3), 117046.

Maeda A, et al. (2026) In vivo visualization of bioactive iron and oxygen using LiON, the labile iron and oxygen notifier. *Cell reports methods*, 6(6), 101431.

Papaioannou G, et al. (2026) Regulation of cAMP levels in osteocytes by mechano-sensitive focal adhesion kinase and phosphodiesterase 8A. *iScience*, 29(6), 116049.

Zacharias NM, et al. (2025) Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma. *Molecular cancer therapeutics*.

Xiang RR, et al. (2025) CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer. *Cell reports*, 44(2), 115312.

Shemorry A, et al. (2025) Engineering ER γ degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases. *Cell chemical biology*, 32(5), 694.

Zengeler KE, et al. (2025) Inflammasome signaling in astrocytes modulates hippocampal plasticity. *Immunity*, 58(6), 1519.

Sine CC, et al. (2025) p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. *Science signaling*, 18(914), eadv0415.

Liu B, et al. (2024) snoRNA-facilitated protein secretion revealed by transcriptome-wide snoRNA target identification. *Cell*.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. *Cancer cell*.

Adachi H, et al. (2023) Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes. *Molecular cell*, 83(4), 637.

Liu C, et al. (2023) Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma. *iScience*, 26(8), 107369.

Mansilla SF, et al. (2023) Polymerase ϵ (Pol ϵ) prevents PrimPol-mediated nascent DNA synthesis and chromosome instability. *Science advances*, 9(15), eade7997.

Duan S, et al. (2023) Clinically Defined Mutations in MEN1 Alter Its Tumor-suppressive Function Through Increased Menin Turnover. *Cancer research communications*, 3(7), 1318.

Glück IM, et al. (2023) Nanoscale organization of the endogenous ASC speck. *iScience*, 26(12), 108382.

Wang Y, et al. (2022) Saturation of the mitochondrial NADH shuttles drives aerobic glycolysis in proliferating cells. *Molecular cell*, 82(17), 3270.

Khandker L, et al. (2022) Cholesterol biosynthesis defines oligodendrocyte precursor heterogeneity between brain and spinal cord. *Cell reports*, 38(9), 110423.

Peterson-Reynolds C, et al. (2022) Differential ER stress as a driver of cell fate following ricin toxin exposure. *FASEB bioAdvances*, 4(1), 60.

Toyomoto M, et al. (2021) S1PR3-G12-biased agonist ALESIA targets cancer metabolism and promotes glucose starvation. *Cell chemical biology*, 28(8), 1132.

Yan P, et al. (2021) LARP7 ameliorates cellular senescence and aging by allosterically enhancing SIRT1 deacetylase activity. *Cell reports*, 37(8), 110038.